Northern Trust’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Northern Trust’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-155,511	Closed	-$3.59M	–	4544
2020 Q4	$3.59M	Sell	155,511 -2,974	-2%	-$37.7K	﹤0.01%	2869
2020 Q3	$1.61M	Buy	158,485 +21,881	+16%	+$294K	﹤0.01%	3157
2020 Q2	$2.04M	Sell	136,604 -20,477	-13%	-$315K	﹤0.01%	3041
2020 Q1	$1.91M	Buy	157,081 +75,725	+93%	+$1.2M	﹤0.01%	2881
2019 Q4	$1.29M	Sell	81,356 -2,269	-3%	-$28.9K	﹤0.01%	3311
2019 Q3	$1.03M	Buy	83,625 +69,386	+487%	+$786K	﹤0.01%	3387
2019 Q2	$188K	Buy	+14,239	New	+$208K	﹤0.01%	3839

Northern Trust's PRVL Position: Q1 2021 in Review

Northern Trust sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 155,511 shares — an estimated $3.59M sold.

Northern Trust first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $3.59M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Northern Trust reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Northern Trust sold 155,511 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $3.59M.
Northern Trust first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
Northern Trust's Prevail Therapeutics Inc. Common Stock position peaked at $3.59M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Northern Trust's 13F filing for Q1 2021, filed 12 May 2021.